Phase I study of PS-341, a novel proteasome inhibitor, in patients with advanced malignancies.

被引：0
|
作者：
Papandreou, CN
Pagliaro, L
Millikan, R
Daliani, D
Herrmann, J
Hong, Y
Smith, M
Adams, J
Elliot, P
Lightcap, E
McCormack, T
Pien, C
Newman, R
Logothetis, CJ
机构：
[1] Univ Texas, Dept Genitourinary Med Oncol, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Leukosite Inc, Cambridge, MA 02139 USA
来源：
CLINICAL CANCER RESEARCH | 1999年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6
引用
收藏
页码：3730S / 3730S
页数：1
相关论文
共 50 条
  • [41] Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC)
    Li, Tianhong
    Ho, Liawaty
    Piperdi, Bilal
    Elrafei, Tarek
    Camacho, Fernando J.
    Rigas, James R.
    Perez-Soler, Roman
    Gucalp, Rasim
    LUNG CANCER, 2010, 68 (01) : 89 - 93
  • [42] A phase II multicenter study of the proteasome inhibitor bortezomib (VELCADE™, formerly PS-341) in multiple myeloma patients (pts) with relapsed/refractory disease.
    Richardson, P
    Barlogie, B
    Berenson, J
    Traynor, A
    Singhal, S
    Jagannath, S
    Irwin, D
    Rajkumar, V
    Srkalovic, G
    Alsina, M
    Alexanian, R
    Siegel, D
    Orlowski, RZ
    Kuter, D
    Limentani, SA
    Lee, S
    Esseltine, DL
    Kauffman, M
    Adams, J
    Schenkein, DP
    Anderson, KC
    BLOOD, 2002, 100 (11) : 104A - 104A
  • [43] A phase I study of sirolimus (rapamycin) and bevacizumab in patients with advanced malignancies.
    Cohen, E. E.
    Sharma, M.
    Janisch, L. A.
    Stadler, W. M.
    Kang, S. P.
    Fleming, G. F.
    Ratain, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] A phase I study of reolysin given intravenously to patients with advanced malignancies.
    Vidal, L.
    Pandha, H.
    Spicer, J.
    Harrington, K. J.
    Allen, S.
    Leader, D.
    Coffey, M.
    Thompson, B.
    Kaye, S.
    De-Bono, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 136S - 136S
  • [45] The proteasome inhibitor PS-341 inhibits the growth of metastatic human prostate cancer in bone.
    Whang, PG
    Iglesias, RC
    Gates, JJ
    Lieberman, JR
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S411 - S411
  • [46] Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts
    Nawrocki, ST
    Bruns, CJ
    Harbison, MT
    Bold, RJ
    Gotsch, BS
    Abbruzzese, JL
    Elliott, P
    Adams, J
    McConkey, DJ
    MOLECULAR CANCER THERAPEUTICS, 2002, 1 (14) : 1243 - 1253
  • [47] A phase I, open label, dose-escalating study of the proteasome inhibitor PS-341 (VELCADE®) in combination with two schedules of trastuzumab, in patients with advanced breast cancer (ABC) that overexpresses HER-2
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 173 - 173
  • [48] Human somatic cell knockouts reveal determinants of sensitivity and resistance to proteasome inhibitor PS-341
    Lee, C
    Waldman, T
    CANCER BIOLOGY & THERAPY, 2003, 2 (06) : 700 - 701
  • [49] Phase II trials of bortezomib (PS-341, Velcade™), a selective proteasome inhibitor, in non-Hodgkin's lymphoma
    不详
    CLINICAL LYMPHOMA, 2003, 4 (02): : 79 - 82
  • [50] The proteasome inhibitor PS-341 sensitizes tumor cells to TRAIL-mediated apoptosis.
    Sayers, TJ
    Brooks, A
    Seki, N
    Murphy, WJ
    Elliott, PJ
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3718S - 3718S
12345